Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
RATIONALE: It is now standard for most breast cancer patients with 1-2 positive sentinel nodes to avoid completion node dissection when eligibility criteria from the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial are met. The National Comprehensive Cancer Network (NCCN) recently proposed to extend this indication to patients that present with biopsy proven node positive disease if only 1 or 2 suspicious nodes are found on imaging, these positive nodes are not palpable clinically, and the other eligibility criteria from the Z0011 study are otherwise met. However, this recommendation is based on an expert consensus and no study has yet confirmed the optimal method to stage the axilla in this patient population. PURPOSE: Evaluate the technical success rate and accuracy of sentinel node biopsy (SNB) and the potential benefits of clipping and removing the biopsy proven node using radioactive seed localisation (RSL) (SNB+RSL = Targeted Axillary Dissection (TAD)) in patients with biopsy proven positive nodes, limited nodal disease in imaging and clinically negative axillary examination.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 lat
- •Rak piersi w stadium T1 lub T2, bez względu na status receptorów
- •Podejrzane węzły chłonne w badaniu USG (maks. dwa)
- •Potwierdzone biopsją zajęcie węzła pachowego
- •Dobry stan sprawności (ECOG <2)
- •Podpisana świadoma zgoda
✗ Disqualifies
- •Wcześniejsza operacja węzłów pachowych, w tym biopsja węzła wartowniczego
- •Przerzuty odległe
- •Wcześniejsza radioterapia węzłów pachowych
- •Wcześniejsze leczenie neoadjuwantowe
- •Uczulenie na barwnik używany do znakowania węzłów
- •Brak zdolności do wyrażenia świadomej zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- February 20, 2025
- Sex
- Female only
Therapies / drugs in trial
Locations (3)
Hôpital Maisonneuve-Rosemont
Montreal, Canada
Centre hospitalier de l'Université de Montréal
Montreal, Canada
Jewish General Hospital
Montreal, Canada
Trial contact
Jean-François Boileau, MD,MSc,FRCSC
Léamarie Meloche-Dumas, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.